Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Raynauds Phenomenon

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Raynauds Phenomenon. Displaying page 1 of 1.
    EudraCT Number: 2014-000865-34 Sponsor Protocol Number: AC-065C202 Start Date*: 2014-09-16
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-center, double-blind, randomized, placebo-controlled, parallel group, exploratory Phase 2 study to assess efficacy and safety of selexipag in adult subjects with Raynaud's Phenomenon second...
    Medical condition: Raynaud's Phenomenon secondary to Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002444-24 Sponsor Protocol Number: HS-18-638 Start Date*: 2020-02-18
    Sponsor Name:Camurus AB
    Full Title: An Exploratory Trial Assessing Vascular Digital Perfusion, Pharmacokinetics, Safety and Tolerability Following a Single Dose of CAM2043 (Treprostinil Subcutaneous Depot) in Patients with Raynaud’s ...
    Medical condition: Raynaud’s phenomenon secondary to systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-001899-38 Sponsor Protocol Number: BAY63-2521/16787 Start Date*: 2013-07-29
    Sponsor Name:Bayer HealthCare AG
    Full Title: Single dose, double-blind, placebo-controlled, single center, randomized cross-over study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after o...
    Medical condition: Patients with 1° and 2° Raynaud’s phenomenon (RP)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019009-40 Sponsor Protocol Number: A7331010 Start Date*: 2010-07-08
    Sponsor Name:Pfizer, S.A.
    Full Title: Estudio clínico de Fase 2A, multicéntrico aleatorizado, doble ciego, controlado con placebo y con un fármaco activo, de diseño cruzado con dos cohortes y dos dosis, para la evaluación de la eficaci...
    Medical condition: Tratamiento del vasospasmo en el fenómeno de Raynaud primario y secundario.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037912 Raynaud's phenomenon LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) CZ (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-013468-37 Sponsor Protocol Number: Protocol code BA7 Start Date*: 2010-09-29
    Sponsor Name:Royal National Hospital for Rheumatic Disease
    Full Title: A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud’s phenomenon.
    Medical condition: Primary Raynaud's Phenomenon and Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10042953 Systemic Sclerosis LLT
    12.0 10037917 Raynaud's phenomenon LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003203-35 Sponsor Protocol Number: VP-C21-004 Start Date*: 2019-12-13
    Sponsor Name:Vicore Pharma AB
    Full Title: A Phase 2, single-center, randomised, double-blind, placebo-controlled, cross-over, cold challenge study investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud’s ...
    Medical condition: Systemic sclerosis (SSc) Raynaud’s phenomenon (RP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-000309-10 Sponsor Protocol Number: CHUBX2017/45 Start Date*: 2021-10-04
    Sponsor Name:CHU de Bordeaux
    Full Title: Phase II/III double-blind randomized placebo-controlled trial assessing the preventive effect of Clopidogrel on the systemic sclerosis development risk in subjects with specific dysimmunity and Ray...
    Medical condition: Raynaud phenomenon
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037914 Raynaud's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024005-13 Sponsor Protocol Number: 3098009 Start Date*: 2011-03-11
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Efficacy of ORM-12741 for prevention of cold-induced vasospasm; a randomised, double-blind, placebo-controlled, single centre crossover study in patient with Raynaud's phenomenon secondary to syste...
    Medical condition: Raynaud's phenomenon secondary to systemic sclerosis (Raynaud's syndrome)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10037914 Raynaud's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002081-13 Sponsor Protocol Number: GS-2001 Start Date*: 2020-09-08
    Sponsor Name:Gesynta Pharma AB
    Full Title: A Phase II, randomised, multi-centre placebo-controlled, double-blind study to investigate the safety of GS-248, and efficacy on Raynaud’s phenomenon (RP) and peripheral vascular blood flow in pati...
    Medical condition: Raynaud's phenomenon (RP) in patients with Systemic sclerosis (SSc)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037917 Raynauds LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004613-24 Sponsor Protocol Number: 01 Start Date*: 2016-05-30
    Sponsor Name:Radboudumc
    Full Title: Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized double-blind placebo-controlled trial.
    Medical condition: (very early) systemic sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001353-16 Sponsor Protocol Number: BAY63-2521/16277 Start Date*: 2015-04-17
    Sponsor Name:Bayer AG
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
    Medical condition: diffuse cutaneous systemic sclerosis (dcSSc)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 07 08:51:35 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA